Edoxaban
- Generic Name
- Edoxaban
- Brand Names
- Lixiana, Savaysa, Roteas
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30ClN7O4S
- CAS Number
- 480449-70-5
- Unique Ingredient Identifier
- NDU3J18APO
- Background
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic em...
- Indication
Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the tr...
- Associated Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism
- Associated Therapies
- -
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2023-06-06
- Target Recruit Count
- 700
- Registration Number
- NCT04297150
- Locations
- 🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain
🇪🇸Hospital Gómez Ulla, Madrid, Spain
🇪🇸Hospital Universitario de La Paz, Madrid, Spain
Oral Anti-coagulants in Fragile Patients With Percutaneous Endoscopic Gastrostomy and Atrial Fibrillation (ORIGAMI) Pilot Study
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 12
- Registration Number
- NCT04271293
- Locations
- 🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT04171726
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
Safety and Efficacy of Edoxaban in Thoracoscopic Ablation
- Conditions
- Interventions
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT04121767
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 150
- Registration Number
- NCT04072068
- Locations
- 🇮🇹
Azienda Ospedalier Spedali Civili di Brescia, Brescia, Italy
🇮🇹Ospedale S.Giacomo, Castelfranco Veneto, Italy
🇮🇹Ospedale di Faenza, Faenza, Italy
DOAC Versus VKA After Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Laval University
- Registration Number
- NCT04002011
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 620
- Registration Number
- NCT03961334
- Locations
- 🇬🇷
Attikon University Hospital, Athens, Greece
🇪🇸Hospital Universitario Virgen Macarena, Sevilla, Spain
🇨🇭University Hospital of Basel, Basel, Switzerland
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
- Conditions
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 1200
- Registration Number
- NCT03950076
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇦🇹Medical University of Innsbruck, Innsbruck, Austria
🇧🇪UZ Brussel, Brussel, Belgium
Resolution of Thrombi in Left Atrial Appendage With Edoxaban
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Keimyung University Dongsan Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT03840291
- Locations
- 🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷Catholic University of Korea, Incheon St. Mary's hospital, Incheon, Korea, Republic of
🇰🇷Pusan National University Hospital, Pusan, Korea, Republic of
Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)
- Conditions
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT03570281
- Locations
- 🇰🇷
Department of Neurology, Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.